Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Genitourinary 3Gastrointestinal 2CNS 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 3Sarcoma 1Pancreatic Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 11Cyclophosphamide 8Gemcitabine 7Cisplatin 7tislelizumab 5Docetaxel 5Nivolumab 4Injections 4spartalizumab 3regorafenib 3Trastuzumab 3Oncolytic Virotherapy 3Irinotecan 3Filgrastim 3Drug Therapy 3Doxorubicin 3Carboplatin 3Bortezomib 3tazemetostat 2pazopanib 2liposomal doxorubicin 2ganitumab 2conatumumab 2belinostat 2Temozolomide 2Taxes 2Tamoxifen 2Sorafenib 2Riluzole 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × ixabepilone × Thoracic × Clear all
NCT01012362 2017-12-28

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
31 enrolled 12 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡